简明回顾：细胞疗法：广泛应用的途径。
Concise review: cell therapies: the route to widespread adoption.
机构信息
Newcastle University Business School, Citywall, Citygate, Newcastle Upon Tyne, United Kingdom.
出版信息
Stem Cells Transl Med. 2012 May;1(5):438-47. doi: 10.5966/sctm.2011-0009. Epub 2012 May 9.
Abstract
We identify three dimensions with which to classify heuristically the routes to widespread adoption of cellular therapies. The first dimension is based on the relative involvement of clinicians and companies in a particular cellular therapy. The second dimension is based on cell type and consequent scale of manufacture. The third dimension classifies the therapeutic intervention as a procedure or product and has perhaps received less attention. We suggest that for those cellular therapies that require therapeutic procedures, close collaboration between companies and clinicians will reduce the time to widespread adoption. For selected cellular therapies we make predictions of the likely time to widespread adoption.
摘要
我们确定了三个维度，可以对细胞疗法广泛应用的途径进行启发式分类。第一个维度基于临床医生和公司在特定细胞疗法中的相对参与程度。第二个维度基于细胞类型和随后的制造规模。第三个维度将治疗干预分为程序或产品，可能受到的关注较少。我们认为，对于那些需要治疗程序的细胞疗法，公司和临床医生之间的密切合作将缩短广泛采用的时间。对于某些选定的细胞疗法，我们对广泛采用的可能时间进行了预测。
相似文献
1
Concise review: cell therapies: the route to widespread adoption.简明回顾：细胞疗法：广泛应用的途径。
Stem Cells Transl Med. 2012 May;1(5):438-47. doi: 10.5966/sctm.2011-0009. Epub 2012 May 9.
2
Emerging immunomodulatory strategies for cell therapeutics.新兴的细胞治疗免疫调节策略。
Trends Biotechnol. 2023 Mar;41(3):358-373. doi: 10.1016/j.tibtech.2022.11.008. Epub 2022 Dec 20.
3
An assessment of the factors affecting the commercialization of cell-based therapeutics: a systematic review protocol.评估影响基于细胞的治疗药物商业化的因素：系统评价方案。
Syst Rev. 2017 Jun 26;6(1):120. doi: 10.1186/s13643-017-0517-4.
4
Therapeutic human cells: manufacture for cell therapy/regenerative medicine.治疗用人类细胞：用于细胞治疗/再生医学的制造。
Adv Biochem Eng Biotechnol. 2014;138:61-97. doi: 10.1007/10_2013_233.
5
Reimbursement and adoption of advanced therapies: the 5-C framework.先进疗法的报销与采用：5C框架
Regen Med. 2014;9(5):573-8. doi: 10.2217/rme.14.51.
6
Tissue formation and tissue engineering through host cell recruitment or a potential injectable cell-based biocomposite with replicative potential: Molecular mechanisms controlling cellular senescence and the involvement of controlled transient telomerase activation therapies.通过宿主细胞募集实现组织形成和组织工程，或具有复制潜力的潜在可注射细胞基生物复合材料：控制细胞衰老的分子机制以及可控瞬时端粒酶激活疗法的参与。
J Biomed Mater Res A. 2015 Dec;103(12):3993-4023. doi: 10.1002/jbm.a.35515. Epub 2015 Aug 14.
7
The early career researcher's toolkit: translating tissue engineering, regenerative medicine and cell therapy products.早期职业研究人员的工具包：转化组织工程、再生医学和细胞治疗产品。
Regen Med. 2015 Nov;10(8):989-1003. doi: 10.2217/rme.15.56. Epub 2015 Dec 2.
8
Regenerative Medicine: Injectable Cell-Based Therapeutics and Approved Products.再生医学：注射型细胞治疗药物和已获批产品。
Adv Exp Med Biol. 2020;1237:75-95. doi: 10.1007/5584_2019_412.
9
Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.用于小规模自动化生产自体细胞产品的学术设施鉴定
Regen Med. 2014;9(6):799-815. doi: 10.2217/rme.14.47.
10
Concise review: adipose-derived stromal vascular fraction cells and platelet-rich plasma: basic and clinical implications for tissue engineering therapies in regenerative surgery.简明综述：脂肪来源的基质血管成分细胞和富含血小板的血浆：在再生外科的组织工程治疗中的基础和临床意义。
Stem Cells Transl Med. 2012 Mar;1(3):230-6. doi: 10.5966/sctm.2011-0054. Epub 2012 Feb 22.
引用本文的文献
1
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.临床开发中的自然杀伤细胞作为非工程化、工程化和联合疗法。
J Hematol Oncol. 2022 Nov 8;15(1):164. doi: 10.1186/s13045-022-01382-5.
2
When craft kicks back: Embryo culture as knowledge production in the context of the transnational fertility industry.当手工制作被淘汰时：跨国生育产业背景下的胚胎培养与知识生产
Soc Stud Sci. 2022 Jun;52(3):425-446. doi: 10.1177/03063127221083869. Epub 2022 Mar 17.
3
Innovative regenerative medicines in the EU: a better future in evidence?欧盟的创新再生医学：更美好的未来是否有迹可循？
BMC Med. 2017 Mar 8;15(1):49. doi: 10.1186/s12916-017-0818-4.
4
Tumor Necrosis Factor α Regulates Endothelial Progenitor Cell Migration via CADM1 and NF-kB.肿瘤坏死因子α通过CADM1和NF-κB调节内皮祖细胞迁移。
Stem Cells. 2016 Jul;34(7):1922-33. doi: 10.1002/stem.2339. Epub 2016 Mar 4.
5
Alginate-Encapsulation for the Improved Hypothermic Preservation of Human Adipose-Derived Stem Cells.藻酸盐包封用于改善人脂肪来源干细胞的低温保存
Stem Cells Transl Med. 2016 Mar;5(3):339-49. doi: 10.5966/sctm.2015-0131. Epub 2016 Jan 29.
6
Looking for the elusive lung stem cell niche.寻找难以捉摸的肺干细胞生态位。
Transl Respir Med. 2014 Apr 3;2:7. doi: 10.1186/2213-0802-2-7. eCollection 2014.
7
The stem cell wars: a dispatch from the front.干细胞之战：来自前线的报道。
Trans Am Clin Climatol Assoc. 2013;124:94-110.
本文引用的文献
1
Mesenchymal Stem Cells: The Past, the Present, the Future.间充质干细胞：过去、现在与未来
Cartilage. 2010 Jan;1(1):6-9. doi: 10.1177/1947603509354992.
2
Past, present and future of myoblast transplantation in the treatment of Duchenne muscular dystrophy.成肌细胞移植治疗杜氏肌营养不良症的过去、现在与未来
Pediatr Transplant. 2010 Nov;14(7):813-9. doi: 10.1111/j.1399-3046.2010.01377.x.
3
Geron trial resumes, but standards for stem cell trials remain elusive.杰龙公司的试验重新开始，但干细胞试验的标准仍然难以确定。
Nat Biotechnol. 2010 Oct;28(10):989-90. doi: 10.1038/nbt1010-989.
4
Regenerative medicine. Opportunities and challenges: a brief overview.再生医学。机遇与挑战：简要概述。
J R Soc Interface. 2010 Dec 6;7 Suppl 6(Suppl 6):S777-81. doi: 10.1098/rsif.2010.0362.focus. Epub 2010 Sep 8.
5
Developing a case study model for successful translation of stem cell therapies.开发一个成功的干细胞疗法翻译案例研究模型。
Cell Stem Cell. 2010 Jun 4;6(6):513-6. doi: 10.1016/j.stem.2010.05.008.
6
Challenges with advanced therapy medicinal products and how to meet them.治疗性药品面临的挑战及其应对措施。
Nat Rev Drug Discov. 2010 Mar;9(3):195-201. doi: 10.1038/nrd3052.
7
Stem cells: roadmap to the clinic.干细胞：通往临床的路线图。
J Clin Invest. 2010 Jan;120(1):8-10. doi: 10.1172/JCI41801.
8
Successful clinical implementation of corneal epithelial stem cell therapy for treatment of unilateral limbal stem cell deficiency.成功地将角膜上皮干细胞治疗应用于单侧角膜缘干细胞缺陷的临床治疗。
Stem Cells. 2010 Mar 31;28(3):597-610. doi: 10.1002/stem.276.
9
Assessing the value of autologous and allogeneic cells for regenerative medicine.评估自体和异体细胞在再生医学中的价值。
Regen Med. 2009 Nov;4(6):835-53. doi: 10.2217/rme.09.64.
10
Human cell culture process capability: a comparison of manual and automated production.人细胞培养工艺能力：手动与自动化生产的比较。
J Tissue Eng Regen Med. 2010 Jan;4(1):45-54. doi: 10.1002/term.217.
Zotero 插件